Part II: The Legislative Environment of Pharmaceutical Marketing

ABSTRACT

In Part II, the editor looks at the Kefauver, Nelson, and Kennedy drug industry hearings and the legislation resulting from the hearigs. Portions of the hearings are prestented, along with analysis and discussion of the ultimate effects of the hearings on the pharmaceutical industry and pharmacy. The editor then offers a defense of pharmaceutical marketing and some possibilities for its future.

KEYWORDS:

• Drug Industry Antitrust Act
• Kefauver hearings
• Nelson hearings
• generic drugs
• drug information
• Kennedy hearings
• Pryor hearings
• Medicare drug benefit
• Waxman-Hatch Act